PURPOSE: Immunocytokine (IC) hu14.18-IL2 is a fusion protein of humanized antidisialoganglioside (GD2) antibody (hu14.18) and interleukin (IL)-2. Sixty-one melanoma and neuroblastoma patients received IC in phase I/Ib studies. Patient sera were examined in ELISA to determine if an anti-IC antibody response occurred during treatment. EXPERIMENTAL DESIGN: Serum was assayed for anti-idiotypic antibody (anti-id Ab) based on ability to bridge biotinylated hu14.18 to plate-bound hu14.18 and ability to inhibit binding of hu14.18 to GD2 antigen and/or murine anti-idiotypic antibody. ELISA was also used to detect antibodies to the Fc-IL2 end of hu14.18-IL2. RESULTS: Thirty-two patients (52%) developed an anti-idiotypic antibody response (absorbance, >0.7) in the bridge ELISA. Twelve patients (20%) had an intermediate response, whereas 17 patients (28%) were negative (adsorbance, <0.3). The development of antibody to hu14.18-IL2 detected in the bridge ELISA was not related to the dose of hu14.18-IL2. Twenty of 33 adult patients (61%) demonstrated an anti-idiotypic antibody response based on binding inhibition ELISA. The anti-idiotypic response was inversely correlated (P < 0.002) with IC measured during the second course of treatment, indicating that development of anti-idiotypic antibodies interfered with detection of circulating hu14.18-IL2. All patients developed some inhibitory activity in the binding inhibition assay designed to detect antibodies to the Fc-IL2 region of the IC. There was a positive correlation between the peak serum level of IC in course 1 and the anti-Fc-IL2 response. CONCLUSIONS: Patients treated with hu14.18-IL2 developed anti-idiotypic antibodies and anti Fc-IL2 antibodies. No association was seen between development of anti-IC antibodies and clinical toxicity.
PURPOSE: Immunocytokine (IC) hu14.18-IL2 is a fusion protein of humanized antidisialoganglioside (GD2) antibody (hu14.18) and interleukin (IL)-2. Sixty-one melanoma and neuroblastomapatients received IC in phase I/Ib studies. Patient sera were examined in ELISA to determine if an anti-IC antibody response occurred during treatment. EXPERIMENTAL DESIGN: Serum was assayed for anti-idiotypic antibody (anti-id Ab) based on ability to bridge biotinylated hu14.18 to plate-bound hu14.18 and ability to inhibit binding of hu14.18 to GD2 antigen and/or murine anti-idiotypic antibody. ELISA was also used to detect antibodies to the Fc-IL2 end of hu14.18-IL2. RESULTS: Thirty-two patients (52%) developed an anti-idiotypic antibody response (absorbance, >0.7) in the bridge ELISA. Twelve patients (20%) had an intermediate response, whereas 17 patients (28%) were negative (adsorbance, <0.3). The development of antibody to hu14.18-IL2 detected in the bridge ELISA was not related to the dose of hu14.18-IL2. Twenty of 33 adult patients (61%) demonstrated an anti-idiotypic antibody response based on binding inhibition ELISA. The anti-idiotypic response was inversely correlated (P < 0.002) with IC measured during the second course of treatment, indicating that development of anti-idiotypic antibodies interfered with detection of circulating hu14.18-IL2. All patients developed some inhibitory activity in the binding inhibition assay designed to detect antibodies to the Fc-IL2 region of the IC. There was a positive correlation between the peak serum level of IC in course 1 and the anti-Fc-IL2 response. CONCLUSIONS:Patients treated with hu14.18-IL2 developed anti-idiotypic antibodies and anti Fc-IL2 antibodies. No association was seen between development of anti-IC antibodies and clinical toxicity.
Authors: K A Foon; J Lutzky; R N Baral; J R Yannelli; L Hutchins; A Teitelbaum; O L Kashala; R Das; J Garrison; R A Reisfeld; M Bhattacharya-Chatterjee Journal: J Clin Oncol Date: 2000-01 Impact factor: 44.544
Authors: Gini F Fleming; Neal J Meropol; Gary L Rosner; Donna R Hollis; William E Carson; Michael Caligiuri; Joanne Mortimer; Katherine Tkaczuk; Robin Parihar; Richard L Schilsky; Mark J Ratain Journal: Clin Cancer Res Date: 2002-12 Impact factor: 12.531
Authors: Kaci L Osenga; Jacquelyn A Hank; Mark R Albertini; Jacek Gan; Adam G Sternberg; Jens Eickhoff; Robert C Seeger; Katherine K Matthay; C Patrick Reynolds; Clare Twist; Mark Krailo; Peter C Adamson; Ralph A Reisfeld; Stephen D Gillies; Paul M Sondel Journal: Clin Cancer Res Date: 2006-03-15 Impact factor: 12.531
Authors: Jonathan W Friedberg; Donna Neuberg; John G Gribben; David C Fisher; Christine Canning; Margaret Koval; Christine M Poor; Luke M Green; John Daley; Robert Soiffer; Jerome Ritz; Arnold S Freedman Journal: Br J Haematol Date: 2002-06 Impact factor: 6.998
Authors: Suzanne Shusterman; Wendy B London; Stephen D Gillies; Jacquelyn A Hank; Stephan D Voss; Robert C Seeger; C Patrick Reynolds; Jennifer Kimball; Mark R Albertini; Barrett Wagner; Jacek Gan; Jens Eickhoff; Kenneth B DeSantes; Susan L Cohn; Toby Hecht; Brian Gadbaw; Ralph A Reisfeld; John M Maris; Paul M Sondel Journal: J Clin Oncol Date: 2010-10-04 Impact factor: 44.544
Authors: Rajen Mody; Alice L Yu; Arlene Naranjo; Fan F Zhang; Wendy B London; Barry L Shulkin; Marguerite T Parisi; Sabah-E-Noor Servaes; Mitchell B Diccianni; Jacquelyn A Hank; Mildred Felder; Jennifer Birstler; Paul M Sondel; Shahab Asgharzadeh; Julia Glade-Bender; Howard Katzenstein; John M Maris; Julie R Park; Rochelle Bagatell Journal: J Clin Oncol Date: 2020-04-28 Impact factor: 44.544
Authors: Maria Carmen Ochoa; Luna Minute; Inmaculada Rodriguez; Saray Garasa; Elisabeth Perez-Ruiz; Susana Inogés; Ignacio Melero; Pedro Berraondo Journal: Immunol Cell Biol Date: 2017-02-21 Impact factor: 5.126
Authors: Wayne L Furman; Sara M Federico; Mary Beth McCarville; Barry L Shulkin; Andrew M Davidoff; Matthew J Krasin; Natasha Sahr; April Sykes; Jianrong Wu; Rachel C Brennan; Michael William Bishop; Sara Helmig; Elizabeth Stewart; Fariba Navid; Brandon Triplett; Victor M Santana; Armita Bahrami; Gwendolyn Anthony; Alice L Yu; Jacquelyn Hank; Stephen D Gillies; Paul M Sondel; Wing H Leung; Alberto S Pappo Journal: Clin Cancer Res Date: 2019-10-10 Impact factor: 12.531
Authors: Aslan Mansurov; Jun Ishihara; Peyman Hosseinchi; Lambert Potin; Tiffany M Marchell; Ako Ishihara; John-Michael Williford; Aaron T Alpar; Michal M Raczy; Laura T Gray; Melody A Swartz; Jeffrey A Hubbell Journal: Nat Biomed Eng Date: 2020-04-13 Impact factor: 25.671
Authors: Mark R Albertini; Richard K Yang; Erik A Ranheim; Jacquelyn A Hank; Cindy L Zuleger; Sharon Weber; Heather Neuman; Greg Hartig; Tracey Weigel; David Mahvi; Mary Beth Henry; Renae Quale; Thomas McFarland; Jacek Gan; Lakeesha Carmichael; KyungMann Kim; Hans Loibner; Stephen D Gillies; Paul M Sondel Journal: Cancer Immunol Immunother Date: 2018-08-03 Impact factor: 6.968